Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ml after Treatment with 5Î±-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer

Article ID	Journal	Published Year	Pages	File Type
3862211	The Journal of Urology	2012	5 Pages	PDF

Abstract

The magnitude of change in serum prostate specific antigen after 5Î±-reductase inhibitor therapy may be useful in diagnosing prostate cancer in patients with persistently increased or fluctuating prostate specific antigen and prior negative prostate biopsy.

Keywords

5AR PSA 5ARI DRE TRUS 5α-reductase Prostate specific antigen Early detection of cancer Prostate volume Dutasteride Prostate cancer transrectal ultrasonography Finasteride digital rectal examination 5α-reductase inhibitor Prostatic neoplasms Benign prostatic hyperplasia BPH prostate-specific antigen CaP